Bortecad 2mg Injection

About

Bortecad 2mg Injection contains Bortezomib, a potent proteasome inhibitor used in the treatment of certain cancers. It works by reversibly inhibiting the 26S proteasome, a multi-catalytic proteinase complex responsible for degrading ubiquitinated proteins. This inhibition disrupts various cellular processes crucial for cancer cell survival, including cell cycle progression, apoptosis, and angiogenesis. By preventing the breakdown of regulatory proteins, Bortezomib leads to the accumulation of misfolded or ubiquitinated proteins, triggering endoplasmic reticulum stress and ultimately inducing programmed cell death (apoptosis) in malignant cells.

Its targeted mechanism makes it particularly effective against hematological malignancies, where it helps to control disease progression and improve patient outcomes. The drug is administered via injection, allowing for precise dosing and systemic distribution to target cancer cells throughout the body. Its clinical efficacy has been well-established in various treatment settings, often in combination with other therapeutic agents.

Uses

• Multiple Myeloma
• Mantle Cell Lymphoma
• Relapsed/Refractory Multiple Myeloma
• Newly diagnosed Multiple Myeloma

Directions For Use

Administered intravenously or subcutaneously by a healthcare professional. Dosage and schedule are determined by the treating physician based on the patient's condition.

Benefits

• Targets cancer cells specifically
• Induces apoptosis in malignant cells
• Effective in various stages of multiple myeloma
• Can be used in combination therapies
• Improves progression-free survival
• Offers a targeted approach to cancer treatment

Side Effects

• Peripheral neuropathy
• Thrombocytopenia
• Neutropenia
• Fatigue
• Nausea
• Diarrhea
• Constipation
• Vomiting
• Anemia
• Fever
• Headache
• Rash

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects or liver strain associated with the medication.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Effective contraception is advised for both male and female patients during and after treatment.
• Breastfeeding - Breastfeeding is not recommended during treatment and for a period after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with moderate to severe hepatic impairment; dose adjustments may be necessary. Liver function should be monitored.
• Kidney - Use with caution in patients with renal impairment; dose adjustments are generally not required for mild to moderate impairment, but close monitoring is advised.
• Lung - Monitor for new or worsening pulmonary symptoms, as interstitial lung disease and pneumonitis have been reported. Seek immediate medical attention for respiratory distress.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.